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Neurodevelopmental Abnormalities in
Children With PHACE Syndrome
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Denise W. Metry, MD6, A. James Barkovich, MD2,7, Ilona J. Frieden, MD7,8, and
Heather J. Fullerton, MD, MAS7,9
Abstract
Prior case reports have identified neurodevelopmental abnormalities in children with PHACE syndrome, a neurocutaneous
disorder first characterized in 1996. In this multicenter, retrospective study of a previously identified cohort of 93 children
diagnosed with PHACE syndrome from 1999 to 2010, 29 children had neurologic evaluations at  1 year of age (median age: 4
years, 2 months). In all, 44% had language delay, 36% gross motor delay, and 8% fine motor delay; 52% had an abnormal neu-
rological exam, with speech abnormalities as the most common finding. Overall, 20 of 29 (69%) had neurodevelopmental
abnormalities. Cerebral, but not posterior fossa, structural abnormalities were identified more often in children with abnormal
versus normal neurodevelopmental outcomes (35% vs. 0%, P ¼ .04). Neurodevelopmental abnormalities in young children with
PHACE syndrome referred to neurologists include language and gross motor delay, while fine motor delay is less frequent.
Prospective studies are needed to understand long-term neurodevelopmental outcomes.
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Infantile hemangiomas are commonbenignneoplasms of the vas-
cular endothelium that are absent at birth, grow rapidly during
infancy, and slowly regress over time.1 Most infantile heman-
giomas are small and well localized; ‘‘segmental’’ infantile
hemangiomas, however, involve a territory of skin and may
be associated with extracutaneous structural abnormalities.2,3
PHACE, an acronym proposed in 1996, is a neurocutaneous syn-
drome that describes the association of segmental infantile
hemangiomas with one or more of the following structural
abnormalities: posterior fossa malformations, arterial anomalies
(cervical and intracranial), cardiovascular anomalies, and eye
anomalies.2,4 In a prospective study of 108 infants with facial
hemangiomas that measured 22 cm2, 33 (31%) met criteria for
PHACE.3
Cerebrovascular anomalies, present in 91% of children with
definite PHACE, is the most common extracutaneous feature of
the disorder, followed by cardiac (67%) and structural brain
anomalies (52%).3 A study of children with cervical and intra-
cranial arterial anomalies in PHACE found that the most com-
mon abnormalities were dysgenesis (56%), anomalous course
or origin (39%), and narrowing (39%).5 Structural brain
abnormalities have been reported in the posterior fossa (32%)
and cerebrum (14%).5 These neuroanatomical and cerebrovas-
cular anomalies may lead to the neurological sequelae that have
been reported in PHACE syndrome, including seizures, stroke,
and developmental delay.3
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Our objective was to use a previously identified cohort of
children with PHACE syndrome to describe their neurodeve-
lopmental abnormalities. A secondary objective was to deter-
mine whether brain structural abnormalities could predict
these neurodevelopmental outcomes.
Methods
This was a multicenter retrospective study of a previously identified
cohort of children with PHACE syndrome from the University of
California, San Francisco Benioff Children’s Hospital, Texas
Children’s Hospital, and Children’s Hospital of Wisconsin.3,5-15
Approval from an ethical standards committee to conduct this study
was received at each site; consent was waived.
Participants
Inclusion criteria were (a) diagnosis of PHACE syndrome by a pedia-
tric dermatologist at any of the 3 participating study centers, meeting
consensus criteria of definite PHACE, between 1999 and 2010, (b) age
< 18 years, and (c) a documented clinical evaluation at 1 year of age
by a child neurologist at any of the 3 participating study centers.
Although the reason for a referral to a neurologist could not be well
categorized in this retrospective study, chart review suggested that
these children were typically referred for abnormalities seen on brain
or cerebrovascular imaging, for concerns regarding development, or
simply because of a diagnosis of PHACE syndrome, without specific
neurologic or developmental concerns.
Medical Record Review
Clinical data were collected from medical records using standardized
data abstraction forms with detailed data abstraction instructions to
ensure consistency across the sites. A single reviewer at each site per-
formed medical record abstraction; University of California, San
Francisco investigators centrally reviewed and analyzed completed
data collection forms. When questions arose regarding the abstracted
data, University of California, San Francisco investigators reviewed
redacted copies of source data, and made coding decisions regarding
specific variables.
We collected data regarding gender, race, maternal age at delivery,
PHACE syndrome characteristics, and pharmacological treatment for
the hemangioma (steroids, propranolol, or vincristine). Congenital
heart defects were defined as the presence of aortic arch anomalies
or other cardiac anomalies associated with PHACE syndrome.4 Patent
ductus arteriosus and patent foramen ovale were not categorized as
defects.
Outcome variables for developmental delay included documented
presence of motor or language delay, use of or referral to physical,
occupational, or speech therapy, and pathological early handedness.
Developmental delay was defined as any documented physician diag-
nosis of fine motor, gross motor, or language delay, or documentation
of delayed milestones: walking at  15 months (gross motor delay);
scribbling at  18 months (fine motor delay); first word at  14
months, less than a 5-word vocabulary at 18 months, or combining
2 words at > 2 years (language delay).
Outcome variables for neurological examination included head cir-
cumference percentile, hypotonia (appendicular or axial), ataxia, and
gait and speech abnormalities. Ataxia included limb ataxia (dysme-
tria) and midline ataxia (truncal or gait ataxia). Gait abnormality was
defined as an unsteady, ataxic, or otherwise impaired gait. Speech
abnormality was defined as dysarthria, aphasia, or other documen-
tation of impaired expressive or receptive language. Other aspects
of the neurological assessment that were abstracted included other
cognitive and behavioral concerns, cranial nerve palsy, Horner’s
syndrome, sensorineural hearing loss, hemiparesis, and hemiatrophy.
Records were also reviewed for diagnoses of stroke, epilepsy, and
chronic headaches.
Neuroradiologic Review
Two neuroradiologists (CPH and AJB), blinded to the clinical data,
reviewed all available brain MRI and magnetic resonance angio-
graphy studies. Arterial anomalies were categorized into dysplastic
or anomalous vessels, and stenotic or hypoplastic vessels. Brain
structural abnormalities were categorized as either infratentorial,
involving the brainstem or cerebellum, or supratentorial, involving
the cerebrum.
Segmental Hemangioma Review
Data regarding the segmental hemangiomas were collected by the
study pediatric dermatologist at each site (IJF, DWM, BAD) on
review of photographs taken with patient consent. Segments were
categorized into S1-S4 on a previously published facial map.16 S1 is
defined as frontotemporal, with involvement of lateral frontal and
anterior temporal scalp. S2 is defined as maxillary, involving the med-
ial and lateral cheek sparing the preauricular region, nasolabial sulcus,
and philtrum. S3 is defined as mandibular, including the skin overly-
ing the mandible, the vermilion lip, and the preauricular region. S4 is
defined as the frontonasal region. Segmental hemangioma data were
further characterized as partially (< 50%) or fully (> 50%) occupying
the specified segment.
Statistical Analysis
All statistical analyses were performed using Stata 11 (College Station,
Tex) and alphawas set at .05. Because our samplewas limited by referral
bias, as only a subset of children with PHACE syndrome was referred to
neurology, our primaryanalysesweredescriptive. In an exploratory anal-
ysis, we tried to identify predictors of neurodevelopmental abnormalities
within this select group of children referred to neurology. To determine
whether data from the 3 sites could be combined, cohort characteristics
and outcome variables were compared between sites using chi-squared
test (or Fisher’s exact, where appropriate) for dichotomous variables and
Kruskal–Wallis rank sum tests for continuous variables. After determin-
ing that therewere no significant differences between sites, the datawere
combined for the remaining analyses.
In our analysis of predictors of neurodevelopmental abnormalities,
our primary outcome variable was a dichotomous composite variable
of abnormal neurodevelopmental outcome, defined as documentation
of any developmental delays and/or any neurological exam abnormal-
ities, or ongoing need for services (physical, occupational, or speech
therapy) after one year of age. Secondary outcomes included motor
delay, language delay, and hypotonia. Predictor variables assessed
were gender, race, location of segmental hemangiomas (S1-S4), brain
structural abnormalities (infratentorial or supratentorial), arterial
anomalies, congenital heart defect, and pharmacological treatment
of the hemangioma. Because hemangioma locations were not
mutually exclusive, each segment (S1-S4) was treated as a dichoto-
mous variable. Proportions of children with and without abnormal
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neurodevelopmental outcome were analyzed using the chi-squared
test (or Fisher’s exact when appropriate). Univariate logistic regres-
sion analysis was used to test for associations and determine odd ratios
and 95% confidence intervals. Similar analyses were done for second-
ary outcomes.
Results
Cohort Characteristics
A total of 93 children received a diagnosis of PHACE syn-
drome from a pediatric dermatologist at 1 of the study centers
and were entered into a registry. Of these, 29 (31%) had a
clinical assessment by a child neurologist at 1 year of age and
were therefore included in this analysis. The proportion with a
neurological evaluation after the first birthday varied by site:
10/21 (48%) at University of California, San Francisco Benioff
Children’s Hospital, 10/35 (29%) at Texas Children’s Hospital,
and 9/37 (24%) at Children’s Hospital of Wisconsin. Cohort
characteristics are summarized in Table 1; characteristics were
similar among the 3 sites (data not shown). As is typical of
PHACE, the majority of patients in the cohort were female
(90%) and white/Caucasian (69%). A total of 13 patients
(45%) were diagnosed with congenital heart defects at the med-
ian age of 3 months (range 0-39 months); the most common
defect was coarctation of the aorta. In all, 10 patients received
corrective cardiac surgery, and 1 patient was placed on bypass
(duration, 72 minutes). Most of the 29 children had clinical
imaging studies available for review: brain MRI (n ¼ 26) and
magnetic resonance angiography (n ¼ 25). Brain structural
abnormalities were seen in 50% of patients with imaging, and
nearly all (92%) had cervical or cerebral arterial anomalies. Of
29 patients, 24 (83%) received corticosteroid treatment with
either prednisone or prednisolone for their hemangioma. These
patients were treated prior to the common use of propranolol in
hemangioma treatment.
Neurodevelopmental abnormalities
Dates of neurological assessments ranged from June 2002 to
July 2010, with the majority of assessments (90%) taking place
in an outpatient setting. A total of 17 patients (59%) had mul-
tiple assessments (> 1 visit). The median age at time of the last
assessment was 4 years, 2 months (range: 1 year 1 month to 12
years). Developmental assessments were documented in 27
(93%) of the 29 children with neurological assessments.
Overall, 19 (70%) of 27 had evidence of developmental
delay, and 15 of 29 (52%) had an abnormal neurologic exam
(Table 2). Motor delay was the most common developmental
delay observed (44%); gross motor delays predominated over
fine motor delays (36% vs 8%). However, the gross motor
delay tended to be mild: the median age at walking among
those 9 children who met our study definition of gross motor
delay was 17 months, with a range of 14-30 months. The child
who walked at 14 months met our study definition because of a
documented physician diagnosis of gross motor delay; the
child’s gross motor skills were noted to be clumsy. Of the 25
children with documented motor development, only 4 (16%)
walked after 18 months of age. Language delay was documen-
ted in 40% of patients, and all those with language delay were
receiving or were referred to speech therapy. Also, 7 patients
(24%) were noted to have other cognitive and behavioral
concerns including impulsivity (n¼ 2), attention-deficit/hyper-
activity disorder (n ¼ 2), ‘‘tactile sensitivity’’ (n ¼ 1), opposi-
tional defiant behaviors (n ¼ 1), moderate mental retardation
(n ¼ 1), and dyslexia (n ¼ 2).
Of the 17 patients who had their head circumference mea-
sured, 3 patients were macrocephalic (> 95th percentile), and
1 was microcephalic (< 5th percentile). Half of the children had
Table 1. Combined Cohort Characteristics for 29 Children With
PHACE Syndrome Evaluated by a Neurologist at  1 Year of Age at
the University of California, San Francisco Benioff Children’s Hospital,
Texas Children’s Hospital, or Children’s Hospital of Wisconsin.
No. Total %
Gender
Female 26 29 90
Race
White/Caucasian 20 29 69
Latino/Hispanic 6 29 21
Native American/Indigenous people 1 29 3
Unknown 2 29 7
Maternal age at delivery, year,
median (range), n ¼ 18
31 (18-42)
Segmental hemangioma
S1 20 27 74
S2 14 27 52
S3 19 27 70
S4 9 27 33
Congenital heart defect 13 29 45
Coarctation of aortic arch 9 29 31
Atrial septal defect 2 29 7
Ventricular septal defect 1 29 3
Tortousity of aortic arch 1 29 3
Tricuspid atresia 1 29 3
Radiologic findings
Arterial anomalies 23 25 92
Dysplasia/anomalous 16 25 64
Stenosis/hypoplasia 12 25 48
Brain structural abnormalities 13 26 50
Infratentorial (posterior fossa)
abnormalities
12 26 46
Hypoplastic/dysplastic cerebellum 12 26 46
Hypoplastic brainstem 2 26 8
Supratentorial abnormalities 6 26 23
Abnormal corpus callosum 2 26 8
Polymicrogyria 1 26 4
Heterotopia 1 26 4
Arterial infarction 1 26 4
Intracranial hemangiomas 3 26 12
Medication
Steroid treatment 24 29 83
Propranolol treatment 4 29 14
Vincristine treatment 3 29 10
Chi-square analysis for differences between each site resulted in P values that
were not statistically significant.
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an abnormal neurological exam; the most common finding
described was an abnormality of speech (33%). Hypotonia was
noted in only 5 (17%). Other neurologic issues included
chronic headaches in 7 (24%), epilepsy in 5 (17%), sensori-
neural hearing loss in 3 (10%), and hemiparesis in 3 (10%).
Documentation of a clinical stroke was noted in the records
of 2 patients, as previously reported.7
Predictors of Neurodevelopmental Abnormalities
Overall, 20 of the 29 children met our composite study defini-
tion of abnormal neurodevelopmental outcome (Table 3). Brain
structural abnormalities were present in 59% of children with
abnormal outcomes, compared to 33% of those with normal
outcomes (P ¼ .22). Although supratentorial (ie, cerebral)
structural abnormalities were less common than infratentorial
ones, they appeared predictive, present in one third of children
with abnormal outcome versus none of children with normal
outcomes (P ¼ .04). Infratentorial lesions were not predictive,
although this study lacked sufficient power to detect a modest
effect.
We performed additional analyses to explore the implica-
tions of infratentorial structural abnormalities on MRI. Of 12
children with infratentorial abnormalities, 6 (50%) had motor
delay, 4 (33%) had language delay, and 3 (25%) had hypotonia.
In univariate analyses, the presence of infratentorial abnormal-
ities did not predict any of these secondary outcomes: odds
ratio 3.0 (95% confidence interval 0.53-17) for motor delay,
1.1 (0.21-6.4) for language delay, and 2.0 (0.27-15) for
hypotonia.
Pharmacological treatment for segmental hemangiomas (eg,
steroids, vincristine, or propanolol) similarly did not predict
either the primary or secondary outcomes (data not shown).
Of the 24 patients who were treated with steroids and had a
neurological assessment at  1 year of age, 5 patients (21%)
had evidence of hypotonia, while 19 patients (79%) had normal
tone.
Discussion
Knowledge of the neurological complications and neurodeve-
lopmental outcomes in PHACE syndrome has been limited to
case reports and small case series. We present the largest cohort
to date of children with neurological assessments, and retro-
spectively describe their early neurodevelopmental abnormal-
ities. The predominant findings included gross motor delay,
language delay, gait and speech abnormalities, and hypotonia.
Supratentorial brain structural abnormalities, though present in
only a quarter of our cohort, appeared to be associated with
abnormal neurodevelopmental outcome.
There are limited data on the neurological morbidity and
outcomes seen in patients with PHACE syndrome. Reports
describing smaller series of children with PHACE syndrome
have described seizures, ‘‘borderline mental level,’’ and devel-
opmental delay.17 Although we cannot describe rates of abnor-
mal outcomes in PHACE syndrome because of the obvious
referral bias in our cohort, we found that 69% of those 29 chil-
dren referred for a neurological assessment after their first
birthday had a documented neurodevelopmental abnormality.
If the 64 children who lacked a neurological evaluation are all
neurologically normal, then the rate of neurodevelopmental
abnormalities would be 22% (20/93), suggesting at least a
lower limit of the rate of abnormal early outcomes. Gross
motor and language delay were the most predominant findings.
However, the motor delay tended to be mild; most children
who met our study definition of gross motor delay still walked
before 18 months of age. Our study measured only early out-
comes; long-term consequences of the brain structural abnorm-
alities in PHACE syndrome may not be apparent in infancy or
early childhood, and children with PHACE syndrome may also
acquire brain injury because of cerebral vascular anomalies.7
Hence, the full impact of PHACE syndrome on neurodevelop-
mental outcomes is underestimated by this study.
Other notable neurologic findings observed in this cohort
included seizures, migraine-like headaches, and sensorineural
hearing loss. Of the 3 patients with sensorineural hearing loss,
2 have been reported in a prior study.8 In that study, Duffy et al
reported hearing loss in 6 patients and suggested that this may
be an underrecognized risk.8 Steroid treatment in children can
affect linear growth and diminish weight gain; however, these
Table 2. Neurological Assessment of 29 Children With PHACE
Syndrome Evaluated by a Neurologist at  1 Year of Age.
No. Totala %
Age at assessment, median
(range)
4 years 2 months
(1-12 years)
Developmental assessment
Any developmental delay 19 27 70
Motor delay 10 25 40
Gross motor 8 25 32
Fine motor 2 25 8
Language delay 10 25 40
Receiving speech therapy 14 28 50
Receiving physical or
occupational
therapy
12 26 46
Other cognitive and
behavioral
concerns
7 29 24
Physical exam
Head circumference
percentile
(n ¼ 17), median (range)
55 (3-100)
Any abnormalities on
neurologic exam
15 29 52
Abnormal speech
(dysarthria, aphasia)
9 27 33
Abnormal gait 6 29 21
Hypotonia 5 29 17
Ataxia 4 29 14
Hemiparesis 3 29 10
Cranial nerve palsy 2 29 7
a The total reflects the number of children who had documented presence or
absence of that feature or finding in their neurological evaluation.
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effects may be transient.18,19 Of children in our cohort who
were treated with steroids, 21% had hypotonia; however, the
incidence of hypotonia was not significantly increased in these
children compared with those that did not receive steroids.
Although our cohort was biased because it included only
those children referred to neurology, we performed an explora-
tory analysis to identify potential predictors of neurodevelop-
mental abnormalities. Supratentorial structural abnormalities
were uncommon but were the only predictor of abnormal out-
come observed in our cohort. These abnormalities included
agenesis of the corpus callosum, gray matter heterotopia, and
polymicrogyria, all of which have been associated with motor
delay, language delay, behavioral disorders, and epilepsy out-
side of the setting of PHACE syndrome.20-23
Infratentorial structural abnormalities were identified in
53% of patients who had an abnormal neurodevelopmental out-
come, versus 33% of those with a normal outcome (odds ratio
2.3, 95% confidence interval 0.42-12). Although this difference
was not significant, our study may have been underpowered to
detect a difference, and prior literature indicates that the poster-
ior fossa may play an important role in neurodevelopment.
Cognitive and psychomotor developmental delays are not
uncommon in patients with posterior fossa abnormalities (such
as Dandy–Walker complex or enlarged cisterna magna).24,25
Speech and language disorders and severe behavioral disorders
can also be seen, in addition to psychomotor developmental
delay, in patients with unilateral cerebellar hypoplasia.26,27
Further studies are needed to assess the significance of infraten-
torial abnormalities in patients with PHACE syndrome. How-
ever, our study suggests that some children with such
abnormalities may have normal outcomes.
The presence of congenital heart defects may also put
children with PHACE syndrome at risk for abnormal neuro-
developmental outcome. Prior studies have identified motor
delays in infants who received cardiac surgery, and suggested
that those requiring surgery as neonates are at particularly
high risk of adverse neurodevelopmental outcomes.28,29 Of
20 children in our study with abnormal neurodevelopmental
outcomes, 6 (29%) had undergone cardiac surgery, compared
to 4 (44%) of those with normal outcomes, but we were likely
underpowered to detect a difference (P ¼ .84).
Stroke, perhaps the most feared complication in PHACE syn-
drome, has been reported in several cases and in some cases been
associated with a moyamoya pattern of vasculopathy.1,7,30-35 In
Table 3. Predictors of Neurodevelopmental Abnormalities Among 29 ChildrenWith PHACE Syndrome Evaluated by a Neurologist at 1 Year
of Age (median: 4 years 2 months, range: 1 to 12 years).
Neurodevelopmental Outcome
Abnormal n ¼ 20 Normal n ¼ 9
No. / Total (%) No. / Total (%) Odds Ratio (95% CI) P value
Female 18 / 20 (90) 8 /9 (89) 0.89 (0.07-11) .93
Race .09*
White/Caucasian 12 / 20 (60) 8 / 9 (89) — —
Latino/Hispanic 6 / 20 (30) 0 / 9 (0) — —
Black/African American — — — —
Asian/Pacific Islander — — — —
Native American/Indigenous people 0 / 20 (0) 1 / 9 (11) — —
Unknown 2 / 20 (10) 0 / 9 (0) — —
Segmented hemangioma
S1 13 / 19 (68) 7 / 8 (88) 0.31 (0.03-3.1) .32
S2 10 / 19 (53) 4 / 8 (50) 1.1 (0.21-5.8) .9
S3 13 / 19 (68) 6 / 8 (75) 0.69 (0.11-4.7) .73
S4 7 /19 (37) 2 / 8 (25) 1.8 (0.27-11) .59
Congenital heart defect 8 / 20 (40) 5 / 9 (56) 0.53 (0.11-2.6) .44
Medication
Steroid treatment 17 / 20 (85) 7 / 9 (78) 1.6 (0.22-12) .64
Vincristine treatment 3 / 20 (15) 0 / 9 (0) — .22
Propanolol treatment 3 / 20 (15) 1 / 9 (11) 1.4 (0.13-16) .78
Radiologic findings
Arterial anomalies, anya 14 / 16 (88) 9 / 9 (100) — .27
Dysplasia/anomalous 9 / 16 (56) 7 / 9 (78) 0.37 (0.06-2.4) .29
Stenosis/hypoplasia 7 / 16 (44) 5 / 9 (56) 0.52 (0.12-3.2) .57
Brain structural abnormalities, anyb 10 / 17 (59) 3 / 9 (33) 2.8 (0.52-15) .22
Infratentorial abnormalities 9 / 17 (53) 3 / 9 (33) 2.3 (0.42-12) .35
Supratentorial abnormalities 6 / 17 (35) 0 / 9 (0) — .04
Intracranial hemangiomasb 3 / 17 (18) 0 / 9 (0) — .18
* P value represents chi-square test for whole group comparison.
a Of 20 children with abnormal outcomes, 16, and all of the 9 children with normal outcomes, had cerebrovascular imaging available for review.
b Of 20 children with abnormal outcomes, 17, and all of the 9 children with normal outcomes, had brain parenchymal MRI available for review.
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our study, only 2 children had received a diagnosis of stroke, as
previously reported.7 However, the retrospective study design
severely limits the ability to understand the true incidence of
stroke in this population. Although cerebrovascular anomalies
were common, few had hemiparesis, which is the most common
finding after childhood stroke.
As indicated above, our study’s greatest limitation was that
we assessed a select cohort of children referred to neurology
clinic; hence, we could not describe the true prevalence of neu-
rodevelopmental abnormalities among children with PHACE
syndrome. Furthermore, only 59% of the children included in
our cohort had > 1 neurological assessment, and the median age
at last assessment was only 4 years, 2 months. Therefore, we
have not captured all neurological sequelae that may be mani-
fested, or acquired, later in life. Long-term follow-up of chil-
dren with PHACE syndrome is needed to better understand
the full impact of this disorder. Our study is also limited by a
small sample size and is underpowered to detect anything but
strong associations. Other limitations are the retrospective
study design, which can result in missing data and misclassifi-
cation. Uncommon variables such as Horner’s syndrome were
assumed to be absent if not mentioned in the medical records.
This presumption may result in the underdetection of some
measured variables within our study.
Children with PHACE syndrome should be monitored for
neurodevelopmental abnormalities so that they can receive
timely and appropriate therapeutic interventions. Dedicated
study of the association of neurological sequelae with neuro-
anatomical abnormalities in this syndrome would provide
important prognostic information to families. Longitudinal
studies must be performed to better understand the risk of
neurological disability associated with PHACE syndrome.
Currently, there is an ongoing prospective study looking at
neurologic, cognitive, and radiologic outcomes in children ages
4-6 years with a diagnosis of PHACE syndrome.
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